There has not been a comprehensive study to determine the changes in the quantity or characteristics of CSCs or circulating tumor cells (CTCs) with EMT phenotype during preoperative anti-HER2 therapy, and whether these changes may predict response to dual anti-HER2 therapy. This evidence concerns the gene ERBB2 and neoplasm.